Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines

Vaccine

Volumn 32, Issue 46, 2014, Pages 6098-6106

  Ward, Brian J ^a   Landry, Nathalie ^b   Trépanier, Sonia ^b   Mercier, Geneviève ^b   Dargis, Michèle ^b   Couture, Manon ^b   D'Aoust, Marc André ^b   Vézina, Louis P ^b  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b Medicago Inc   (Canada)

Author keywords

Allergy; Bromelain assay; CCDs; Cross reactive carbohydrate determinants; Humoral response; IgE; IgG; Influenza A virus; Plant made vaccines; Plant specific glycans

Indexed keywords

AVIDIN; BROMELAIN; GLYCAN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PLANT MEDICINAL PRODUCT; TRIPLE VACCINE; VIRUS LIKE PARTICLE VACCINE; ALLERGEN; POLYSACCHARIDE;

ADULT; ALLERGIC RHINITIS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CROSS REACTION; DEGLYCOSYLATION; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HAY FEVER; HEMAGGLUTINATION INHIBITION; HUMAN; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MAJOR CLINICAL STUDY; NICOTIANA BENTHAMIANA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; ADOLESCENT; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEMAGGLUTINATION INHIBITION TEST; HYPERSENSITIVITY; IMMUNOLOGY; INFLUENZA VIRUS A; MAIZE; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TOBACCO; YOUNG ADULT;

ADOLESCENT; ADULT; ALLERGENS; ANTIBODY FORMATION; CROSS REACTIONS; DOUBLE-BLIND METHOD; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INFLUENZA VACCINES; MIDDLE AGED; POLYSACCHARIDES; TOBACCO; VACCINES, VIRUS-LIKE PARTICLE; YOUNG ADULT; ZEA MAYS;

EID: 84908003879     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.079     Document Type: Article

References (27)

1. Landry N., Ward B.J., Trépanier S., Montomoli E., Dargis M., Lapini G., et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010, 5(Dec (12)):e15559.
2. Aviezer D., Brill-Almon E., Shaaltiel Y., Hashmueli S., Bartfeld D., Mizrachi S., et al. A plant-derived recombinant human glucocerebrosidase enzyme-a preclinical and phase I investigation. PLoS One 2009, 4(3):e4792.
3. Foetisch K., Westphal S., Lauer I., Retzek M., Altmann F., Kolarich D., et al. Biological activity of IgE specific for cross-reactive carbohydrate determinants. J Allergy Clin Immunol 2003, 111(Apr (4)):889-896.
4. Van Ree R., Cabanes-Macheteau M., Akkerdass J., Milazzo J.P., Loutelier-Bourhis C., Rayon C., et al. β(1,2)-Xylose and α(1,3)-fucose residues have a strong contribution in IgE binding to plant glycoallergens. J Biol Chem 2000, 275(15):11451-11458.
5. Van der Veen M.J., van Ree R., Aalberse R.C., Akkerdaas J., Koppelman S.J., Jansen H.M., et al. Poor biologic activity of cross-reactive IgE directed to carbohydrate determinants of glycoproteins. J Allergy Clin Immunol 1997, 100(3):327-334.
6. Ebo D.G., Hagendorens M.M., Bridts C.H., De Clerck L.S., Stevens W.J. Sensitization to cross-reactive carbohydrate determinants and the ubiquitous protein profilin: mimickers of allergy. Clin Exp Allergy 2004, 34(Jan (1)):137-144.
7. Altmann F. The role of protein glycosylation in allergy. Int Arch Allergy Immunol 2007, 142(2):99-115.
8. Schein C.H., Ivanciuc O., Midoro-Horiuti T., Goldblum R.M., Braun W. An allergen portrait gallery: representative structures and an overview of IgE binding surfaces. Bioinf Biol Insights 2010, Oct (4):113-125.
9. Kaulfürst-Soboll H., Mertens M., Brehler R., von Schaewen A. Reduction of cross-reactive carbohydrate determinants in plant foodstuff: elucidation of clinical relevance and implications for allergy diagnosis. PLoS One 2011, 6(Mar (3)):e17800.
10. Fujiyama K., Sakai Y., Misaki R., Yanagihara I., Honda T., Anzai H., et al. N-linked glycan structures of human lactoferrin produced by transgenic rice. Biosci Biotechnol Biochem 2004, 68:2565-2570.
11. Mari A., Ooievaar-de Heer P., Scala E., Giani M., Pirrotta L., Zuidmeer L., et al. Evaluation by double-blind placebo-controlled oral challenge of the clinical relevance of IgE antibodies against plant glycans. Allergy 2008, 63:891-896.
12. Tacket C.O. Plant-based oral vaccines: results of human trials. Curr Top Microbiol Immunol 2009, 332:103-117.
13. Blake T.A., Williams T.L., Pirkle J.L., Barr J.R. Targeted N-linked glycosylation analysis of H5N1 influenza hemagglutinin by selective sample preparation and liquid chromatography/tandem mass spectrometry. Anal Chem 2009, 81(Apr (8)):3109-3118.
14. Bardor M., Faveeuw C., Fitchette A.C., Gilbert D., Galas L., Trottein F., et al. Immunoreactivity in mammals of two typical plant glycol-epitopes, core α(1-3)-fucose and core xylose. Glycobiology 2003, 13(6):427-434.
15. Eberlein B., Krischan L., Darsow U., Ollert M., Ring J. Double positivity to bee and wasp venom: improved diagnostic procedure by recombinant allergen-based IgE testing and basophil activation test including data about cross-reactive carbohydrate determinants. J Allergy Clin Immunol 2012, 130(Jul (1)):155-161.
16. D'Aoust M.A., Couture M.M., Charland N., Trépanier S., Landry N., Ors F., et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 2010, 8(Jun (5)):607-619.
17. Commins S.P., Platts-Mills T.A. Allergenicity of carbohydrates and their role in anaphylactic events. Curr Allergy Asthma Rep 2010, 10(Jan (1)):29-33.
18. Kelso J.M. Adverse reactions to vaccines for infectious diseases. Middleton's allergy principles & practice 2009, 1189-1204. Mosby, PA, USA. N.F. Adkinson, B.S. Bochner, W.W. Busse, S.T. Holgate, R.F. Lemanske, F.E.R. Simons (Eds.).
19. Bohlke K., Davis R.L., Marcy S.M., Braun M.M., DeStefano F., Black S.B., et al. Vaccine safety datalink team. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003, 112(Oct (4)):815-820.
20. Chung E.H. Vaccine allergies. Clin Exp Vaccine Res 2014, 3:50-57.
21. Andersen D.V., Jørgensen I.M. MMR vaccination of children with egg allergy is safe. Dan Med J 2013, 60:A4573.
22. Gagnon R., Primeau M.N., Des Roches A., Lemire C., Kagan R., Carr S., et al. PHAC-CIHR influenza research network. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. J Allergy Clin Immunol 2010, 126:317-323.
23. Kelso J.M. Update on vaccination guidelines for allergic children. Expert Rev Vaccines 2009, 8(Nov (11)):1541-1546.
24. Chung E.Y., Huang L., Schneider L. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 2010, 125(May (5)):e1024-e1030.
25. Bencúrová M., Hemmer W., Focke-Tejkl M., Wilson I.B., Altmann F. Specificity of IgG and IgE antibodies against plant and insect glycoprotein glycans determined with artificial glycoforms of human transferrin. Glycobiology 2004, 14(May (5)):457-466.
26. van Ree R. Carbohydrate epitopes and their relevance for the diagnosis and treatment of allergic diseases. Int Arch Allergy Immunol 2002, 129(Nov (3)):189-197.
27. Uermösi C., Beerli R.R., Bauer M., Manolova V., Dietmeier K., Buser R.B., et al. Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol 2010, 126(Aug (2)):375-383.